The Clinical Efficacy and Cost-Effectiveness of Two Kinds of Imipenem/Cilastatin Sodium Formulations for Febrile Neutropenia:A Controlled Clinical Trial
摘要：
Objective: To evaluate the clinical efficacy and cost-effectiveness of two kinds of imipenem/cilastatin sodium formulations: Bacqure and Tienam for febrile neutropenia.Methods: Fifty one cases of patients with febrile neutropenia were randomly divided into two groups.Bacqure was used in one group(29 cases) and the other group(22 cases) was treated with Tienam.Evaluate the efficacy of the two groups and use the pharmacological economic principle to analyze the cost-effectiveness of the two groups.Results: The effective rates of Bacqure group and Tienam group in the treatment of febrile neutropenia were 86.20 % and 86.36 %(P0.05) respectively;the cost-effectiveness ratio(C/E) were 28.54 and 42.15.The cost for every one unit increment of effectiveness in Tienam group was 7,375 RMB,which was higher than that in Bacqure group.Conclusions: There was no significant difference between Bacqure group and Tienam group in the clinical efficacy for febrile neutropenia.The cost-effectiveness ratio of Bacqure is superior to that of Tienam and Bacqure is likely to have pharmacoeconomical advantage over Tienam in the treatment of febrile neutropenia.
展开
被引量：
年份：
2013
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
